Study of the Fecal Microbiome in Patients With Parkinson's Disease

Inclusion Criteria:

- Documented diagnosis of Parkinson's Disease (PD) for less than or equal to 10 years
based on the United Kingdom Brain Bank Criteria and the Modified Hoehn-Yahr (H&Y)
staging system of less than 3 in the "OFF medicine" state of at least 8-12 hours
(subjects should have an asymmetric and unilateral symptoms onset).

- Mild microsomia to anosmia (The University of Pennsylvania Smell Identification Test
(UPSIT) less than 33), which is supportive of idiopathic PD.

- Robust response to dopaminergic therapy (defined as greater than 33% reduction in
symptoms (on the Unified Parkinson's Disease Rating Scale part III (UPDRS-III)) when
measured in the ON medicine state compared to OFF state.

- Subject has a history of constipation.

- Sexually active male and female subjects of child-bearing potential agree to use an
effective method of birth control during the study.

- Female subjects of child-bearing potential must have a negative urine Qualitative
Human chorionic gonadotropin (hCG) pregnancy test at enrollment and on the Week 1, Day
1 of the Treatment prior to administration of study drug.

- Willing and able to sign an informed consent form and attend study assessments and
follow ups.

- Subject has an attending physician who will provide non-transplant care for the
subject.

- Subject is able to maintain a stable Parkinson's therapy medical regimen during
participation in the study.

Exclusion Criteria:

- Unable to take multiple capsules orally.

- Montreal Cognitive Assessment (MoCA) Score less than or equal to 23.

- Atypical, vascular or drug-induced Parkinsonism.

- Clinical features of psychosis or refractory hallucinations.

- Unstable Parkinson's disease symptomatic therapy (defined as recent changes or
additions to the PD regimen).

- Compromised immune system (e.g. primary immune disorders or clinical immunosuppression
due to a medical condition or medication e.g. taking systemic steroids greater than 20
milligrams (mg) a day or prednisone-equivalent)

- Receipt of systemic non-topical antibiotic therapy currently or within 14 days of
enrollment.

- Prior Deep Brain Stimulation, or surgical intervention for PD, intravenous glutathione
therapy or stem cell therapy.

- History of medium or large vessel cerebrovascular accidents.

- History of use of an investigational drug within 90 days prior to the screening visit.

- Positive results for human immunodeficiency virus (HIV) or Hepatitis B / C.

- Current history for active states of Inflammatory bowel disease, Irritable bowel
syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy,
colectomy, gastrointestinal fistulae or strictures.

- History of significant uncontrolled systemic disease that in the opinion of the study
investigator could interfere with study participation and/or objectives.

- Life expectancy of less than 1 year.

- In the opinion of investigator, subject for any reason, should be excluded from the
study